Efficacy of tenofovir on clinical outcomes of COVID-19 patients: a systematic review.

ABSTRACT:

Background

Pharmacological treatments for COVID-19 remain limited, particularly for severe outcomes. Tenofovir, an inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), has been proposed as a therapeutic agent to reduce hospitalization, intensive care unit (ICU) admissions, and mortality.

Objective

To assess the efficacy of tenofovir in COVID-19 patients based on randomized controlled trials (RCTs).

Methods

A systematic review of RCTs assessing tenofovir in COVID-19 was conducted. Searches in PubMed/MEDLINE, Scopus, Cochrane Library, LILACS, SciELO, and COVID-19 LOVE databases were last updated on April 16, 2025. Risk of bias was evaluated using the Cochrane Risk of Bias 2.0 tool. As a meta-analysis was not feasible, a qualitative analysis was performed. Th

SUBMITTER: Sales TLS 

PROVIDER: S-EPMC12312381 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature